You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CD22 CAR-T

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

B Acute Lymphoblastic Leukemia, Ph-Negative ALL, High Risk Acute Lymphoblastic Leukemia Trial (Azacitidine Injection,

Not yet recruiting
  • B Acute Lymphoblastic Leukemia
  • +2 more
  • Azacitidine Injection
  • +2 more
  • (no location specified)
Oct 15, 2023

Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Trial in Suzhou (Obinutuzumab, Zanubrutinib, Lenalidomide)

Enrolling by invitation
  • Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
  • Suzhou, Jiangsu, China
    the First Affiliated Hospital of Soochow University
Mar 22, 2023

B-cell Acute Lymphoblastic Leukemia, B Lineage Lymphoblastic Lymphoma Trial in Philadelphia (Autologous, humanized anti-CD22 CAR

Recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • B Lineage Lymphoblastic Lymphoma
  • Autologous, humanized anti-CD22 CAR T cell therapy (CART22-65s)
  • Autologous, humanized anti-CD19 CAR T cell therapy (huCART19)
  • Philadelphia, Pennsylvania
    Children's Hospital of Philadelphia
Jan 25, 2023

B Cell Lymphoma, Acute Lymphoblastic Leukemia, Pediatric, Lymphoma Trial in Stanford (Fludarabine, Cyclophosphamide, Autologous

Suspended
  • B Cell Lymphoma
  • +2 more
  • Stanford, California
    Stanford Medical Center
Sep 8, 2022

Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia Trial in Tianjin (CD19-CD22 CAR-T cells)

Active, not recruiting
  • Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia
  • CD19-CD22 CAR-T cells
  • Tianjin, China
    Institute of Hematology & Blood Diseases Hospital
Aug 2, 2022

B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma, Diffuse Large B Cell Lymphoma Trial in Beijing (CD19/CD22-bispecific CAR-T

Recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • +2 more
  • CD19/CD22-bispecific CAR-T cells
  • Beijing, Beijing, China
    Liang Wang
Oct 7, 2023

CNS Lymphoma Trial in Nanchang (Human CD19-CD22 Targeted T Cells Injection)

Recruiting
  • Central Nervous System Lymphoma
  • Human CD19-CD22 Targeted T Cells Injection
  • Nanchang, Jiangxi, China
    The Second Affiliated Hospital of Nanchang University
Dec 13, 2022

Recurrent Acute Lymphoblastic Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Prolymphocytic Leukemia Trial

Recruiting
  • Recurrent Acute Lymphoblastic Leukemia
  • +15 more
  • Anti-CD19/CD20/CD22 CAR T-Cells
  • +2 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Nov 4, 2022

Leukemia, Lymphoma Trial in Canada, United States (Patient-derived CD19- and CD22 specific CAR)

Recruiting
  • Leukemia
  • Lymphoma
  • Patient-derived CD19- and CD22 specific CAR
  • Los Angeles, California
  • +4 more
Apr 2, 2022

Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoblastic Leukemia Trial in Beijing

Recruiting
  • Acute Lymphoblastic Leukemia
  • +2 more
  • Autologous humanized anti-CD22 chimeric antigen receptor T cells
  • Beijing, Beijing, China
    Beijing Boren Hospital
Aug 12, 2022

Leukemia Trial in Seattle (Patient-derived CD22-specific CAR T-cells also expressing an EGFRt)

Active, not recruiting
  • Leukemia
  • Patient-derived CD22-specific CAR T-cells also expressing an EGFRt
  • Seattle, Washington
    Seattle Children's Hospital
Feb 15, 2022

Lymphoma, B-Cell Trial in Langfang (CD19 and CD22 targeted CAR-T cells)

Not yet recruiting
  • Lymphoma, B-Cell
  • CD19 and CD22 targeted CAR-T cells
  • Langfang, Hebei, China
    Hebei Yanda Ludaopei Hospital
Dec 6, 2022

B-ALL, B-cell Non Hodgkin Lymphoma, DLBCL Trial in Stanford (Fludarabine, Cyclophosphamide, CD22 CAR)

Recruiting
  • B-ALL
  • +3 more
  • Stanford, California
    Stanford Medical Center
Jan 14, 2022

Lymphoid Leukemia Trial in Palo Alto (Allogeneic donor-derived T-cells transduced with bivalent lentiviral vector

Not yet recruiting
  • Lymphoid Leukemia
  • Allogeneic donor-derived T-cells transduced with bivalent lentiviral vector (CD19/CD22-BBz) chimeric antigen receptor (CAR)
  • Treg CD34+ HSPC (Orca-T)
  • Palo Alto, California
    Stanford Cancer Center
Aug 17, 2022

Non-Hodgkin Lymphoma Trial in Aurora (CD19x22 CAR T Cells)

Active, not recruiting
  • Non-Hodgkin Lymphoma
  • CD19x22 CAR T Cells
  • Aurora, Colorado
    University of Colorado Hospital
Sep 1, 2022

Acute Lymphoblastic Leukemia Trial in Shanghai (Human CD19-CD22 Targeted T Cells Injection)

Not yet recruiting
  • Acute Lymphoblastic Leukemia
  • Human CD19-CD22 Targeted T Cells Injection
  • Shanghai, Shanghai, China
    Ruijin Hospital, Shanghai Jiao Tong University School of Medicin
Jan 24, 2022

Acute Lymphoid Leukemia, B-Cell Leukemia, Leukemia, Lymphocytic, B Cell Trial run by the National Cancer Institute (NCI)

Not yet recruiting
  • Acute Lymphoid Leukemia
  • +4 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Aug 17, 2022

B Cell Malignancies Trial in Shenzhen (bi-4SCAR CD19/22 T cells)

Recruiting
  • B Cell Malignancies
  • bi-4SCAR CD19/22 T cells
  • Shenzhen, Guangdong, China
    Shenzhen Geno-immune Medical Institute
Jun 21, 2022

Leukemia, Lymphoma Trial in United States (SCRI-CAR22v2)

Recruiting
  • Leukemia
  • Lymphoma
  • SCRI-CAR22v2
  • Los Angeles, California
  • +4 more
Jan 18, 2023

B-ALL Trial in Moscow (CD19/CD22 CAR-T)

Recruiting
  • B-ALL
  • CD19/CD22 CAR-T
  • Moscow, Russian Federation
    Federal Research Institute of Pediatric Hematology, Oncology and
Jul 23, 2021

Solid Tumor, Adult, Cervical Cancer, Sarcoma Trial in Shijiazhuang (Autologous aPD-L1 armored anti-CD22 CAR T cells)

Recruiting
  • Solid Tumor, Adult
  • +3 more
  • Autologous aPD-L1 armored anti-CD22 CAR T cells
  • Shijiazhuang, Hebei, China
    Fourth Hospital of Hebei Medical University
May 25, 2021

Cancer, Relapsed/Refractory Large B-cell Lymphoma (LBCL) Trial (Fludarabine (30 mg/m^2), Cyclophosphamide (500 mg/m^2), CRG-022

Not yet recruiting
  • Cancer
  • Relapsed/Refractory Large B-cell Lymphoma (LBCL)
  • Fludarabine (30 mg/m^2)
  • +2 more
  • (no location specified)
Jul 25, 2023

CD19+ and CD 22+ B-ALL Trial in Langfang (Autologous CD19/CD22 Chimeric Antigen Receptor T-cells, Cyclophosphamide,Fludarabine)

Recruiting
  • CD19+ and CD 22+ B-ALL
  • Langfang, Hebei, China
    Hebei Yanda Ludaopei Hospital
Jan 25, 2022

B-cell Acute Lymphoblastic Leukemia Trial in Suzhou (CD22/CD19 CAR T and auto-HSCT "sandwich" strategy)

Recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • CD22/CD19 CAR T and auto-HSCT "sandwich" strategy
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University
Jul 20, 2022

B-cell Non Hodgkin Lymphoma, B-cell Chronic Lymphocytic Leukemia Trial in Milwaukee (Dose Level -1: 0.75x10^6 cells/kg

Recruiting
  • B-cell Non Hodgkin Lymphoma
  • B-cell Chronic Lymphocytic Leukemia
  • Dose Level -1: 0.75x10^6 cells/kg CAR20.19.22 cells
  • +3 more
  • Milwaukee, Wisconsin
    Medical College of Wisconsin and Froedtert Hospital
Jul 1, 2022